Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tenofovir DF vs Stavudine in Antiretroviral-Naive HIV-1 (Study 903)
NCT00158821Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Mar 2000
- Primary completion
- Dec 2001
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of tenofovir disoproxil fumarate in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by Gilead Sciences. Primary endpoints: Proportion of patients with HIV-1 RNA levels less than 50 copies/mL at Week 48 and Safety, efficacy and tolerability of the two treatment regimens at Week 144. Started Mar 2000; status: completed.
02
Drugs
tenofovir disoproxil fumarate
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT00158821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00158821.